AR112601A1 - Métodos para predecir la utilidad de modificaciones aminoacídicas específicas de enfermedad para inmunoterapia - Google Patents
Métodos para predecir la utilidad de modificaciones aminoacídicas específicas de enfermedad para inmunoterapiaInfo
- Publication number
- AR112601A1 AR112601A1 ARP180101552A AR112601A1 AR 112601 A1 AR112601 A1 AR 112601A1 AR P180101552 A ARP180101552 A AR P180101552A AR 112601 A1 AR112601 A1 AR 112601A1
- Authority
- AR
- Argentina
- Prior art keywords
- methods
- immunotherapy
- disease
- acid modifications
- specific amino
- Prior art date
Links
- 238000000034 method Methods 0.000 title abstract 3
- 150000001413 amino acids Chemical class 0.000 title abstract 2
- 201000010099 disease Diseases 0.000 title abstract 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 2
- 238000009169 immunotherapy Methods 0.000 title abstract 2
- 238000012986 modification Methods 0.000 title abstract 2
- 206010028980 Neoplasm Diseases 0.000 abstract 3
- 102000004196 processed proteins & peptides Human genes 0.000 abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 2
- 239000000427 antigen Substances 0.000 abstract 1
- 238000009566 cancer vaccine Methods 0.000 abstract 1
- 229940022399 cancer vaccine Drugs 0.000 abstract 1
- 230000004048 modification Effects 0.000 abstract 1
- 229920001184 polypeptide Polymers 0.000 abstract 1
- 238000002255 vaccination Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001154—Enzymes
- A61K39/001156—Tyrosinase and tyrosinase related proteinases [TRP-1 or TRP-2]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001184—Cancer testis antigens, e.g. SSX, BAGE, GAGE or SAGE
- A61K39/001188—NY-ESO
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/80—Vaccine for a specifically defined cancer
- A61K2039/876—Skin, melanoma
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70514—CD4
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
- G01N2333/70517—CD8
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Molecular Biology (AREA)
- Urology & Nephrology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Physics & Mathematics (AREA)
- Analytical Chemistry (AREA)
- Biotechnology (AREA)
- Food Science & Technology (AREA)
- Cell Biology (AREA)
- Pathology (AREA)
- General Physics & Mathematics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Métodos para predecir si los péptidos o polipéptidos que comprenden modificaciones aminoacídicas específicas de enfermedad, en particular neo-antígenos asociados a tumores, comprenden epítopos, en particular neo-epítopos asociados a tumores, que son útiles para inmunoterapia, tal como para vacunación. Los métodos pueden usarse, en particular, para la provisión de vacunas que son específicas contra el tumor de un paciente y, por ende, en el contexto de vacunas personalizadas contra el cáncer.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/EP2017/064140 WO2018224166A1 (en) | 2017-06-09 | 2017-06-09 | Methods for predicting the usefulness of disease specific amino acid modifications for immunotherapy |
Publications (1)
Publication Number | Publication Date |
---|---|
AR112601A1 true AR112601A1 (es) | 2019-11-20 |
Family
ID=59227704
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP180101552 AR112601A1 (es) | 2017-06-09 | 2018-06-08 | Métodos para predecir la utilidad de modificaciones aminoacídicas específicas de enfermedad para inmunoterapia |
Country Status (14)
Country | Link |
---|---|
US (1) | US20200209251A1 (es) |
EP (1) | EP3635408A1 (es) |
JP (2) | JP7396903B2 (es) |
KR (1) | KR102560750B1 (es) |
CN (1) | CN110741260B (es) |
AR (1) | AR112601A1 (es) |
AU (1) | AU2018279117A1 (es) |
BR (1) | BR112019022349A2 (es) |
CA (1) | CA3066308A1 (es) |
IL (1) | IL271031A (es) |
MA (1) | MA49246A (es) |
SG (2) | SG11201911618UA (es) |
TW (1) | TW201920959A (es) |
WO (2) | WO2018224166A1 (es) |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP4046651A1 (en) * | 2021-02-23 | 2022-08-24 | baseclick GmbH | Method for producing an mrna tumor vaccine |
CN115620810B (zh) * | 2022-12-19 | 2023-03-28 | 北京诺禾致源科技股份有限公司 | 基于第三代基因测序数据的外源插入信息的检测方法和装置 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ATE512160T1 (de) * | 2005-04-26 | 2011-06-15 | Immatics Biotechnologies Gmbh | T-cell-epitope aus dem unreifen lamininrezeptorprotein (oncofoetal antigen) und deren medizinische verwendungen |
AU2012261237B2 (en) * | 2011-05-24 | 2017-06-01 | BioNTech SE | Individualized vaccines for cancer |
EP2925348B1 (en) * | 2012-11-28 | 2019-03-06 | BioNTech RNA Pharmaceuticals GmbH | Individualized vaccines for cancer |
CA2919567A1 (en) * | 2013-07-30 | 2015-02-05 | Biontech Ag | Tumor antigens for determining cancer therapy |
WO2016128060A1 (en) * | 2015-02-12 | 2016-08-18 | Biontech Ag | Predicting t cell epitopes useful for vaccination |
GB201511191D0 (en) * | 2015-06-25 | 2015-08-12 | Immatics Biotechnologies Gmbh | T-cell epitopes for the immunotherapy of myeloma |
-
2017
- 2017-06-09 WO PCT/EP2017/064140 patent/WO2018224166A1/en active Application Filing
-
2018
- 2018-06-01 CN CN201880038102.9A patent/CN110741260B/zh active Active
- 2018-06-01 EP EP18728389.0A patent/EP3635408A1/en active Pending
- 2018-06-01 AU AU2018279117A patent/AU2018279117A1/en active Pending
- 2018-06-01 MA MA049246A patent/MA49246A/fr unknown
- 2018-06-01 US US16/620,459 patent/US20200209251A1/en active Pending
- 2018-06-01 BR BR112019022349-5A patent/BR112019022349A2/pt unknown
- 2018-06-01 SG SG11201911618UA patent/SG11201911618UA/en unknown
- 2018-06-01 CA CA3066308A patent/CA3066308A1/en active Pending
- 2018-06-01 JP JP2019568031A patent/JP7396903B2/ja active Active
- 2018-06-01 KR KR1020197035862A patent/KR102560750B1/ko active IP Right Grant
- 2018-06-01 WO PCT/EP2018/064468 patent/WO2018224405A1/en active Application Filing
- 2018-06-01 SG SG10201912475XA patent/SG10201912475XA/en unknown
- 2018-06-08 TW TW107119773A patent/TW201920959A/zh unknown
- 2018-06-08 AR ARP180101552 patent/AR112601A1/es unknown
-
2019
- 2019-11-28 IL IL271031A patent/IL271031A/en unknown
-
2023
- 2023-11-30 JP JP2023202429A patent/JP2024026224A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
CN110741260B (zh) | 2024-03-08 |
EP3635408A1 (en) | 2020-04-15 |
BR112019022349A2 (pt) | 2020-05-26 |
US20200209251A1 (en) | 2020-07-02 |
SG11201911618UA (en) | 2020-01-30 |
MA49246A (fr) | 2020-04-15 |
RU2019139982A (ru) | 2021-07-09 |
JP2020523016A (ja) | 2020-08-06 |
TW201920959A (zh) | 2019-06-01 |
KR20200014311A (ko) | 2020-02-10 |
WO2018224405A1 (en) | 2018-12-13 |
WO2018224166A1 (en) | 2018-12-13 |
RU2019139982A3 (es) | 2021-07-09 |
CN110741260A (zh) | 2020-01-31 |
JP2024026224A (ja) | 2024-02-28 |
SG10201912475XA (en) | 2020-02-27 |
AU2018279117A1 (en) | 2020-01-02 |
JP7396903B2 (ja) | 2023-12-12 |
CA3066308A1 (en) | 2018-12-13 |
IL271031A (en) | 2020-01-30 |
KR102560750B1 (ko) | 2023-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2022000012A (es) | Prediccion de epitopos de celulas t utiles para vacunacion. | |
CL2021001744A1 (es) | Péptidos y combinaciones de péptidos para el uso en la inmunoterapia contra el cáncer de próstata y otros tipos de cáncer (divisional de la solicitud no. 201800324) | |
CY1124176T1 (el) | Προβλεψη ανοσογονiκοτητας των επιτοπων των t κυτταρων | |
AR122964A2 (es) | Péptidos útiles en la inmunoterapia contra el carcinoma hepatocelular (chc) y otros tipos de cáncer | |
CR20180027A (es) | Nuevos péptidos y nuevas combinaciones de péptidos para el uso en la misma terapia contra el cáncer epitelial de ovario y otros tipos de cáncer. | |
MX2019010972A (es) | Receptores de linfocito t (tcr) específicos del antígeno asociado a melanoma 1 (mage-a1) de alta afinidad y usos de estos. | |
CR20190276A (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza | |
CR20160531A (es) | Inmunoterapia novedosa contra varios tumores de la sangre, como la leucemia mielógena aguda (lma) | |
CR20170419A (es) | Nuevos péptidos y nueva combinación de péptidos para el uso en la inmunoterapia contra el cáncer de páncreas y otros tipos de cáncer. | |
CR20180174A (es) | Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer | |
BR112019011450A2 (pt) | células naturais killer modificadas e uso das mesmas | |
PE20181538A1 (es) | Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc) | |
MY189028A (en) | Anti-cd123 chimeric antigen receptor (car) for use in cancer treatment | |
EA201690868A1 (ru) | Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга | |
BR112018073221A2 (pt) | métodos de previsão da utilidade de proteínas ou seus fragmentos, métodos de seleção e/ou avaliação de modificações de aminoácidos específicas, método de fornecimento de vacinas e vacina | |
UY37594A (es) | Biomarcador inmunologico para predecir el efecto clinico de inmunoterapia del cancer | |
CL2018002458A1 (es) | Péptidos, ácidos nucleicos, vectores de expresión y células para la utilización en inmunoterapia contra el cáncer (divisional solicitud 201600227) | |
CL2019002948A1 (es) | Nuevos péptidos y combinación para el uso en la inmunoterapia contra varios tipo de cáncer. (divisional solicitud 201801533) | |
AR112601A1 (es) | Métodos para predecir la utilidad de modificaciones aminoacídicas específicas de enfermedad para inmunoterapia | |
WO2016011432A3 (en) | Identification of immunogenic mhc class ii peptides for immune-based therapy | |
AR108688A1 (es) | Vector de vacuna de levadura que incluye polipéptidos inmunoestimuladores y antigénicos, métodos para su uso | |
CL2019001537A1 (es) | Nuevos receptores de células t y terapia inmunológica que los utiliza. | |
AR105775A1 (es) | Vacunas terapéuticas contra el hpv18 | |
MX2019013161A (es) | Inmunoterapia personalizada contra diversos tumores cerebrales y neuronales. | |
EA201990696A1 (ru) | Персонализированная иммунотерапия нескольких видов нейрональных опухолей и опухолей головного мозга |